$RDGL - Vivos Inc Retains Well-Know OTC Markets An

$RDGL - Vivos Inc Retains Well-Know OTC Markets Analyst, George Sharp, as Advisor

https://finance.yahoo.com/news/vivos-inc-reta...00556.html

Richland, WA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant to OTC Market’s Group, George Sharp, as an advisor to the company. Mr. Sharp will advise Vivos on its business strategy, financing endeavors and its commitment to investor interests.

Vivos Inc. President, Mike Korenko, stated, “As we discovered from an unsolicited July 17, 2018 article written by George and posted on his blog, George is very supportive of our efforts towards developing cancer treatments, and to date, Vivos remains the only microcap issuer that he has ever endorsed.”

Mr. Korenko went on to say, “George's experience as an advocate for individual investors in the microcap space, has garnered him a significant following, and his respect is a commodity valued by Vivos. We look forward to George’s continued contribution as we endeavor to execute on the agreements outlined in our previous press release to eliminate the toxic debt and provide critical funding for product development.”

Recognizing Mr. Sharp’s value to the microcap market, OTC Markets Group, an operator of financial markets and provider of the platform on which the shares of Vivos trade, has engaged George's expertise in tracking small and microcap market activity in support of their efforts to improve market transparency.

"I am thrilled for the opportunity to work with Vivos’ management and I am encouraged by their dedication to create a valuable company that can improve therapeutic results and quality of life for those needing treatment and reward investors for their support of this important effort. This is a genuine a commitment rarely found within the OTC Markets”, stated George Sharp. "I look forward to making my small contribution towards finding less invasive treatments for cancer through my continued support of the company."

About Vivos Inc. (RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.